Kostas Biliouris
Stock Analyst at Oppenheimer
(1.12)
# 3,821
Out of 5,146 analysts
64
Total ratings
35.29%
Success rate
-16.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $22 | $12.03 | +82.88% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $27.14 | +128.45% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $18.79 | +166.10% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $326.81 | +43.81% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $81.58 | -14.19% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.38 | +189.86% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $4.35 | +84.12% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $72.75 | -1.02% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $15.75 | +217.46% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.50 | +354.55% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $13.59 | +267.92% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.12 | +725.24% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.53 | +1,011.11% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $10.05 | +298.01% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $19.50 | +361.54% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $30.68 | +85.79% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $65.41 | -43.43% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $61.66 | +62.18% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $4.09 | +365.12% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $56.04 | +74.88% | 1 | Jun 17, 2022 |
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $12.03
Upside: +82.88%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $27.14
Upside: +128.45%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $18.79
Upside: +166.10%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $326.81
Upside: +43.81%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $81.58
Upside: -14.19%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.38
Upside: +189.86%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $4.35
Upside: +84.12%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $72.75
Upside: -1.02%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $15.75
Upside: +217.46%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.50
Upside: +354.55%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $13.59
Upside: +267.92%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.12
Upside: +725.24%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.53
Upside: +1,011.11%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $10.05
Upside: +298.01%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $19.50
Upside: +361.54%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $30.68
Upside: +85.79%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $65.41
Upside: -43.43%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $61.66
Upside: +62.18%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $4.09
Upside: +365.12%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $56.04
Upside: +74.88%